Performed within GENEWIZ from Azenta Life Sciences' CLIA-certified and CAP-accredited state-of-the-art clinical genomics laboratory
The new facility significantly increases Siegfried’s R&D capacity to drive development excellence and further growth
HYMPAVZI’s approval is based on Phase 3 study results demonstrating non-inferiority and superiority compared to routine prophylaxis in eligible patients with hemophilia A or B without inhibitors
Jagsonpal Pharmaceuticals has received full consideration of Rs. 41 crore towards the sale of the facility and will now be proceeding with registration formalities
With 6 operation hubs and 18 offices across North America, Europe, and Asia, Indegene’s client base includes the world’s top 20 biopharma companies
Launch of new product range aligns with strategy to diversify into emerging applications with high growth potential
Aromatic L-amino acid decarboxylase deficiency is a rare genetic disorder that affects the production of some neurotransmitters
Opinion granted based on positive overall survival results from the IND.227/KEYNOTE-483 trial
This includes $2 billion of new investment creating more than a thousand new, high-skilled jobs
Subscribe To Our Newsletter & Stay Updated
